Skip Navigation



Europace Advance Access published online on November 3, 2009

Europace, doi:10.1093/europace/eup349
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bertaglia, E.
Right arrow Articles by Stabile, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertaglia, E.
Right arrow Articles by Stabile, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.


CLINICAL RESEARCH

Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: a 6-year multicentre experience

Emanuele Bertaglia1,*, Claudio Tondo2, Antonio De Simone3, Franco Zoppo1, Massimo Mantica4, Pietro Turco3, Assunta Iuliano5, Giovanni Forleo4, Vincenzo La Rocca3 and Giuseppe Stabile5

1 Ospedale Civile di Mirano, Via Ca'Rossa, 35, 30173 Venezia, Italy; 2 Ospedale San Camillo, Rome, Italy; 3 Clinica San Michele, Maddaloni (CE), Italy; 4 Istituto Clinico Sant'Ambrogio, Milano, Italy; 5 Clinica Mediterranea, Napoli, Italy

Aims: In the last decade, several approaches to ablating triggers and substrates of atrial fibrillation (AF) have been developed. However, most studies have reported data only on short- or medium-term follow-up. The aim of this study was to investigate whether the 1-year efficacy of catheter ablation for AF is predictive of long-term clinical success.

Methods and results: Between February 2001 and October 2003, 229 consecutive patients affected by drug-refractory paroxysmal or persistent AF underwent a single radiofrequency catheter ablation procedure (anatomical approach in 146 patients and electrophysiologically guided approach in 83 patients). Of these patients, 177 (mean age 59.1 ± 10.5 years, 57.6% with paroxysmal AF) were free from any atrial arrhythmia recurrence after 12 months. These 177 patients were subsequently followed up for at least another 24 months, by means of electrocardiogram and 24 h Holter monitoring. After a mean follow-up of 49.7 ± 13.3 months (range 36–83 months), 58.2% of the patients were free from any atrial arrhythmia recurrence (39.5% without antiarrhythmic drugs). The actuarial atrial arrhythmia recurrence rate was 13.0% at 2 years, 21.8% at 3 years, 35.0% at 4 years, 46.8% at 5 years, and 54.6% at 6 years. Atrial arrhythmia-free survival was similar in patients with paroxysmal or persistent AF, with and without antiarrhythmic drugs during the follow-up, who underwent electrophysiologically guided pulmonary vein (PV) isolation or anatomical PV ablation.

Conclusion: Even patients in whom catheter ablation prevents AF recurrence for 1 year should not be considered ‘cured’, since >40% of them will suffer AF recurrence over a long-term clinical follow-up.

Key Words: Atrial fibrillation, Catheter ablation, Long-term results


* Corresponding author. Tel: +39 0415794253, Fax: +39 0415794309, Email: bertagliaferro{at}alice.it

Manuscript submitted 9 March 2009. Accepted after revision 13 October 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.